Last reviewed · How we verify
Actos (Pioglitazone)
Actos (Pioglitazone) is a Thiazolidinediones Small molecule drug developed by Taipei Veterans General Hospital, Taiwan. It is currently FDA-approved. Also known as: Pioglitazone.
Actos (pioglitazone) is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues, particularly in adipose tissue, skeletal muscle, and liver.
Pioglitazone, also known as Actos, is a small molecule medication used to treat various conditions, including fatty liver, as indicated by clinical trials on ClinicalTrials.gov. Its mechanism of action is not specified in the provided facts, but it is listed as a small molecule on ChEMBL.
At a glance
| Generic name | Actos (Pioglitazone) |
|---|---|
| Also known as | Pioglitazone |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Drug class | Thiazolidinediones |
| Target | PPAR-γ |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Mechanism of action
Actos works by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which increases the expression of genes involved in glucose metabolism and lipid storage.
Approved indications
Boxed warnings
- Heart Failure
- Bladder Cancer
Common side effects
- Edema
- Weight gain
- Headache
- Upper respiratory tract infection
- Sinusitis
- Myalgia
- Dizziness
Drug interactions
- CYP2C8 inhibitors (e.g., gemfibrozil) may increase pioglitazone levels
- CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone levels
- Concomitant use with insulin or other antidiabetic agents may increase the risk of hypoglycemia
Key clinical trials
- Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) (PHASE1, PHASE2)
- The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD (PHASE4)
- Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude (PHASE4)
- A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy (PHASE4)
- Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS (NA)
- A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer (PHASE1)
- SGLT2i, Pioglitazone, and Ketone Production in T2D (PHASE1)
- Effect Clomiphene vs Clomiphene Along With Pioglitazone on Ovarian Stimulation Rate (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US5594016A |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actos (Pioglitazone) CI brief — competitive landscape report
- Actos (Pioglitazone) updates RSS · CI watch RSS
- Taipei Veterans General Hospital, Taiwan portfolio CI
Frequently asked questions about Actos (Pioglitazone)
What is Actos (Pioglitazone)?
How does Actos (Pioglitazone) work?
Who makes Actos (Pioglitazone)?
Is Actos (Pioglitazone) also known as anything else?
What drug class is Actos (Pioglitazone) in?
What development phase is Actos (Pioglitazone) in?
What are the side effects of Actos (Pioglitazone)?
What does Actos (Pioglitazone) target?
Related
- Drug class: All Thiazolidinediones drugs
- Target: All drugs targeting PPAR-γ
- Manufacturer: Taipei Veterans General Hospital, Taiwan — full pipeline
- Therapeutic area: All drugs in Metabolic
- Also known as: Pioglitazone
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing